Alvotech Resubmits Biologics License Applications for AVT05 and AVT06 to FDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2026
0mins
Alvotech (ALVO) announced the resubmission to the FDA of biologics license applications, or BLAs, for AVT05, a proposed biosimilar to Simponi and Simponi Aria, and AVT06, a proposed biosimilar to Eylea 2 mg. Under a partnership with Teva (TEVA), Alvotech is responsible for the development and manufacturing of AVT05 and AVT06, while Teva is responsible for commercialization. The resubmissions follow the submission of Alvotech's response to the FDA's post-application action letter, or PAAL, related to the company's Reykjavik manufacturing facility. In addition, the company has submitted responses to observations from a routine cGMP surveillance FDA inspection at the facility, completed in May. The company expects the FDA to conduct a six-month review of the resubmitted applications, consistent with the applicable regulatory timelines. AVT03, Alvotech's proposed biosimilar to Prolia and Xgeva, is partnered with Dr. Reddy's (RDY) which, as applicant, is responsible for the U.S. regulatory submission.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALVO
Wall Street analysts forecast ALVO stock price to rise
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 3.460
Low
5.00
Averages
8.75
High
10.00
Current: 3.460
Low
5.00
Averages
8.75
High
10.00
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alvotech Secures $75 Million Financing
- Credit Agreement Amendment: Alvotech has amended its existing credit agreement with GoldenTree Asset Management to access an additional $75 million, enhancing its financial flexibility to support the development of biosimilars.
- Loan Facility Details: The initial loan facility amount is $100 million with a monthly interest rate of 12.5%, maturing on December 31, 2027, indicating the company's proactive planning for future capital needs.
- Total Capital Increase: This financing raises Alvotech's total accessible capital to $240 million, combined with the previously reported $165 million from a private placement, providing ample funding for its biologics license applications.
- FDA Review Progress: Alvotech's biosimilar application for Entyvio has been accepted for review by the FDA, indicating that the company's strategic positioning in the biopharmaceutical sector is gradually making progress.
See More
Alvotech Secures $75M New Term Loan Facility
- Financing Agreement Amendment: Alvotech announced an amendment to its existing credit agreement, securing a new term loan facility of up to $75 million, led by long-term partner GoldenTree Asset Management LP alongside other existing lenders, reflecting strong market confidence in the company.
- Total Capital Raised: This loan, combined with the $165 million equity capital raise completed on June 18, 2026, gives Alvotech access to a total of $240 million in fresh capital, enhancing its financial flexibility to support future growth initiatives.
- Loan Terms Details: The new loan carries an interest rate of 12.50% per annum, with monthly cash interest payments due, maturing on December 31, 2027, further expanding Alvotech's existing $100 million credit framework and improving its capital management capabilities.
- Market Outlook: This financing not only strengthens Alvotech's competitive position in the biosimilars sector but also provides essential funding for future product development and market expansion, demonstrating its strategic positioning within the industry.
See More
Alvotech Secures $75 Million Loan to Boost Growth Strategy
- Financial Strengthening: Alvotech has amended its credit agreement to secure an additional $75 million term loan facility maturing on December 31, 2027, which will enhance the company's financial position and support its biosimilar R&D and global product launches.
- Significant Capital Raise: This financing follows Alvotech's recent $165 million equity raise on June 18, 2026, bringing the total new capital secured to $240 million, significantly improving cash flow and operational flexibility.
- Accelerated Strategic Execution: The new funds will be utilized to advance Alvotech's biosimilar pipeline and support the launch of key biologics, which is expected to significantly enhance the company's competitiveness and market share globally.
- Increased Investor Confidence: Founder Robert Wessman noted that strong backing from over 40 new investors reflects growing market confidence in Alvotech's strategy and future opportunities, further solidifying its leadership position in the biosimilars sector.
See More
Celtic Lux Acquires Alvotech Shares
- Share Acquisition Announcement: Celtic Lux Holdings S.a. r.l. acquired 10,133,333 shares of Alvotech at a price of $3.75 per share on June 16, 2026, indicating confidence in Alvotech's future and potentially impacting its market performance.
- Management Transaction Disclosure: The transaction has been filed with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF), reflecting the company's commitment to transparency and compliance, which may enhance investor trust.
- Shareholder Structure Change: The acquisition by Celtic Lux Holdings may lead to changes in Alvotech's shareholder structure, further influencing the company's governance and strategic decisions, potentially paving the way for future capital operations.
- Market Reaction Expectations: The announcement of this acquisition may attract market attention to Alvotech's stock, prompting investors to reassess its investment value, thereby affecting its stock price volatility.
See More
Alvotech Closes $26.07 Million Public Offering
- Offering Amount: Alvotech announced the closing of a $26.07 million public offering at a price of $3.75 per share, with a concurrent offering expected to raise an additional $17.83 million, leading to total gross proceeds of approximately $165 million, indicating strong market interest in the company.
- Use of Proceeds: The funds raised will be allocated towards advancing the development of its biosimilar assets and supporting working capital and general corporate purposes, reflecting the company's ongoing commitment to innovation in the biotechnology sector.
- Shareholder Participation: The Alvotech Board has approved the issuance of $43.89 million in shares to investors participating in the offering and concurrent private placement, with total issued share capital expected to reach approximately 39.04 million shares, thereby strengthening the company's capital structure.
- Market Performance: Although the company's stock is currently trading at $3.87, down 1.15%, the successful completion of this offering may provide essential funding for future growth and enhance investor confidence in the company's prospects.
See More
Alvotech Completes $165 Million Public Offering and Private Placement
- Successful Offering: Alvotech closed its public offering of 26,066,667 ordinary shares at $3.75 per share on June 17, 2026, generating approximately $98 million in gross proceeds, indicating strong market demand for its biosimilar products.
- Concurrent Private Placement: Alongside the public offering, Alvotech entered into subscription agreements with professional investors to issue 17,826,666 ordinary shares at the same price, expected to raise around $67 million, thereby enhancing the company's financial strength.
- Clear Use of Proceeds: The net proceeds from both the offering and private placement will be allocated to the continued development of biosimilar assets, working capital, and general corporate purposes, including intellectual property protection and clinical development, demonstrating the company's strategic planning for future growth.
- Capital Structure Adjustment: Following the completion of the offering, Alvotech's total share capital will amount to 390,431,480 shares, reflecting the company's active presence in the capital markets and its attractiveness to investors, further solidifying its position in the biopharmaceutical sector.
See More
Alvotech Secures $75 Million Financing
- Credit Agreement Amendment: Alvotech has amended its existing credit agreement with GoldenTree Asset Management to access an additional $75 million, enhancing its financial flexibility to support the development of biosimilars.
- Loan Facility Details: The initial loan facility amount is $100 million with a monthly interest rate of 12.5%, maturing on December 31, 2027, indicating the company's proactive planning for future capital needs.
- Total Capital Increase: This financing raises Alvotech's total accessible capital to $240 million, combined with the previously reported $165 million from a private placement, providing ample funding for its biologics license applications.
- FDA Review Progress: Alvotech's biosimilar application for Entyvio has been accepted for review by the FDA, indicating that the company's strategic positioning in the biopharmaceutical sector is gradually making progress.
See More
Alvotech Secures $75M New Term Loan Facility
- Financing Agreement Amendment: Alvotech announced an amendment to its existing credit agreement, securing a new term loan facility of up to $75 million, led by long-term partner GoldenTree Asset Management LP alongside other existing lenders, reflecting strong market confidence in the company.
- Total Capital Raised: This loan, combined with the $165 million equity capital raise completed on June 18, 2026, gives Alvotech access to a total of $240 million in fresh capital, enhancing its financial flexibility to support future growth initiatives.
- Loan Terms Details: The new loan carries an interest rate of 12.50% per annum, with monthly cash interest payments due, maturing on December 31, 2027, further expanding Alvotech's existing $100 million credit framework and improving its capital management capabilities.
- Market Outlook: This financing not only strengthens Alvotech's competitive position in the biosimilars sector but also provides essential funding for future product development and market expansion, demonstrating its strategic positioning within the industry.
See More
Alvotech Secures $75 Million Loan to Boost Growth Strategy
- Financial Strengthening: Alvotech has amended its credit agreement to secure an additional $75 million term loan facility maturing on December 31, 2027, which will enhance the company's financial position and support its biosimilar R&D and global product launches.
- Significant Capital Raise: This financing follows Alvotech's recent $165 million equity raise on June 18, 2026, bringing the total new capital secured to $240 million, significantly improving cash flow and operational flexibility.
- Accelerated Strategic Execution: The new funds will be utilized to advance Alvotech's biosimilar pipeline and support the launch of key biologics, which is expected to significantly enhance the company's competitiveness and market share globally.
- Increased Investor Confidence: Founder Robert Wessman noted that strong backing from over 40 new investors reflects growing market confidence in Alvotech's strategy and future opportunities, further solidifying its leadership position in the biosimilars sector.
See More
Celtic Lux Acquires Alvotech Shares
- Share Acquisition Announcement: Celtic Lux Holdings S.a. r.l. acquired 10,133,333 shares of Alvotech at a price of $3.75 per share on June 16, 2026, indicating confidence in Alvotech's future and potentially impacting its market performance.
- Management Transaction Disclosure: The transaction has been filed with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF), reflecting the company's commitment to transparency and compliance, which may enhance investor trust.
- Shareholder Structure Change: The acquisition by Celtic Lux Holdings may lead to changes in Alvotech's shareholder structure, further influencing the company's governance and strategic decisions, potentially paving the way for future capital operations.
- Market Reaction Expectations: The announcement of this acquisition may attract market attention to Alvotech's stock, prompting investors to reassess its investment value, thereby affecting its stock price volatility.
See More
Alvotech Closes $26.07 Million Public Offering
- Offering Amount: Alvotech announced the closing of a $26.07 million public offering at a price of $3.75 per share, with a concurrent offering expected to raise an additional $17.83 million, leading to total gross proceeds of approximately $165 million, indicating strong market interest in the company.
- Use of Proceeds: The funds raised will be allocated towards advancing the development of its biosimilar assets and supporting working capital and general corporate purposes, reflecting the company's ongoing commitment to innovation in the biotechnology sector.
- Shareholder Participation: The Alvotech Board has approved the issuance of $43.89 million in shares to investors participating in the offering and concurrent private placement, with total issued share capital expected to reach approximately 39.04 million shares, thereby strengthening the company's capital structure.
- Market Performance: Although the company's stock is currently trading at $3.87, down 1.15%, the successful completion of this offering may provide essential funding for future growth and enhance investor confidence in the company's prospects.
See More
Alvotech Completes $165 Million Public Offering and Private Placement
- Successful Offering: Alvotech closed its public offering of 26,066,667 ordinary shares at $3.75 per share on June 17, 2026, generating approximately $98 million in gross proceeds, indicating strong market demand for its biosimilar products.
- Concurrent Private Placement: Alongside the public offering, Alvotech entered into subscription agreements with professional investors to issue 17,826,666 ordinary shares at the same price, expected to raise around $67 million, thereby enhancing the company's financial strength.
- Clear Use of Proceeds: The net proceeds from both the offering and private placement will be allocated to the continued development of biosimilar assets, working capital, and general corporate purposes, including intellectual property protection and clinical development, demonstrating the company's strategic planning for future growth.
- Capital Structure Adjustment: Following the completion of the offering, Alvotech's total share capital will amount to 390,431,480 shares, reflecting the company's active presence in the capital markets and its attractiveness to investors, further solidifying its position in the biopharmaceutical sector.
See More
